Researches, develops, manufactures and sells pharmaceutical products including active pharmaceutical ingredients and formulations such as penicillin, cephalosporins, and vitamins; over 1,000 products across more than ten subsidiaries, with operations headquartered in Hebei Province and the listed entity registered in Wan Chai, Hong Kong.
Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1992
No trial phase data available
No trial data available
No trial data available
No approval data available
- DelveInsight's 2025 pipeline report reveals 18+ active companies developing 20+ cancer cachexia therapies, addressing a critical unmet need in oncology care. - Key developments include Endevica Bio's TCMCB07 entering Phase II trials and CSPC's JMT203 receiving FDA approval for US clinical studies. - Cancer cachexia affects up to 87% of pancreatic and gastric cancer patients and accounts for approximately 22% of cancer-related deaths. - The therapeutic landscape includes diverse mechanisms targeting growth factors, melanocortin receptors, and adrenergic pathways through various administration routes.
• CanSino Biologics Inc. (CanSinoBIO) has received approval from China's medical products regulator to begin clinical trials for its mRNA COVID-19 vaccine candidate. • Pre-clinical studies suggest the CanSinoBIO mRNA vaccine elicits high levels of neutralizing antibodies against multiple variants, including Omicron. • China, with approximately 88% of its population vaccinated, is advancing domestically developed mRNA vaccine candidates, as foreign-made mRNA vaccines are yet to be approved.
